You are here

Please fill in the NICE 'Topic suggestion' form

we understand that DOH/NICE have no plans to for an appraisal of Dasatinib as therapy for CML. We as patients and group organisers can make our dismay known to NICE by filling in the form and suggesting Dasatinib as a 'topic for apraisal. on their website NICE provided a section called
'suggest a topic' where we can as a group and as individuals, put forward Dasatinib as a topic for appraisal. CML Support will be doing this but i strongly suggest that as many individuals as possible take some time to fill in this form. it is simple to do and may help to convince NICE/DOH to change their minds.

copy and past url below for NICE website and online form........

www.nice.org.uk/page.aspx?o=ts.form

My partner and I have each completed the form

Craig A

Me too. I just hope it makes a difference to hear from us all.
Janet

I have also done it.Hope it helps with us all supporting this very important Drug for CML.

Steven D

It may be of interest to identify how NICE decide on guidance topics, the following is an extract from their web site.
Interestingly, it is down to Ministers at the Department of Health who will make final decisions about which topics are referred to NICE!! Maybe we ought to be lobbying our politicians as well as approaching NICE directly in this way.

How guidance topics are chosen
The Department of Health commissions NICE to develop clinical guidelines, guidance on public health and technology appraisals. Topics for the interventional procedures program are notified to NICE directly, usually by clinicians.

The topics NICE considers come from a number of sources:

clinical and public health professionals, patients, carers and the general public the Department of Health's national clinical directors and policy teams the National Horizon Scanning Centre (they suggest new and emerging health technologies that might need to be assessed) suggestions from within NICE itself. The Department of Health carried out a public consultation on the topic selection process from March - June 2006. As a result NICE was asked to manage the administration of the early stages of the topic selection process on behalf of the Department of Health. Topics suggested since January 2006 onwards will be managed by NICE under the new process. Ministers at the Department of Health will continue to retain responsibility for the final decision about which topics are referred to NICE.

Paul

Me too!

I see from the NICE Email acknowledging receipt, that if the suggestion is rejected, they should tell you within a month. Let's hope I don't hear anything for longer than that because it might be a sign that it is being considered in more detail.

David

Mine is in.

Zavie Miller (age 68)
Ottawa, Canada, dxd AUG/99
INF OCT/99 to FEB/00, CHF
Gleevec since MAR/27/01 (400 mg)
CCR SEP/01. #102 in Zero Club
2.8 log reduction Sep/05
3.0 log reduction Jan/06
> 4 log reduction Nov/06
zmiller@sympatico.ca

Done. Takes me back to 2001 when we went through this to get STI571 (Glivec) accepted. Peter Capel

The title says it all. Here we go again. Imatinib revisited.

Chris

Done, thanks for letting us know about this.

Bill